JANX
Janux Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$17.47Close
$1.1BMarket cap
$12.18 – $34.7452-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 50% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
50%
1wk
up 4.9%
price change
1mo
up 1.1%
price change
12-month return
down 39%
market up 11% ·
its own down 48%
F-score
—
— Not assessed
Altman Z
14.28
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.1×
price / book
Earnings yield
down 15.7%
EBIT / enterprise value
Cheaper than
35%
of the market · expensive
Revenue growth
down 6%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 11%
return on equity
Free cash margin
down 833%
-$83.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.0%
$0.87 a day · 2×ATR $15.73
RS
59 / 99
vs the universe
Trend
5 / 8
under the 50-day, over 25% off the high, RS under 70
Relative volume
0.6×
vs 50-day average
Up/down volume
1.22
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 2.2% over the year, from 59m to 60m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 5.6% over the year, from $10.6M to $10.0M.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-1% vs market2 sessions after results
Financials
- Net -1136%
- Free cash -833%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $3.6M | $8.6M | $8.1M | $10.6M | $10.0M |
| Operating income | -$4.8M | -$32.9M | -$67.1M | -$73.0M | -$98.8M | -$157.7M |
| Net income | -$6.8M | -$32.7M | -$63.1M | -$58.3M | -$69.0M | -$113.6M |
| Net margin | — | -898% | -732% | -721% | -652% | -1136% |
| Earnings per share | -$29.03 | -$1.39 | -$1.52 | -$1.32 | -$1.28 | -$1.83 |
| Free cash flow | -$4.4M | -$18.5M | -$49.4M | -$52.4M | -$44.2M | -$83.3M |
| Free cash margin | — | -508% | -573% | -649% | -417% | -833% |
| Cash | $7.8M | $35.6M | $51.4M | $19.2M | $430.6M | $52.3M |
| Shareholders' equity | -$14.6M | $366.3M | $320.7M | $344.3M | $1.0B | $956.8M |
| Shares outstanding | 1.05m | 41.24m | 41.62m | 46.25m | 59.06m | 60.38m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 8, 2024 | Annual ↗ | Dec 31, 2023 | 68d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jun 23, 2026 | Other events ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Apr 28, 2026 | Director or officer change ↗ |
| Feb 26, 2026 | Results ↗ |
| Jan 22, 2026 | Material agreement · Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Sep 19, 2025 | Director or officer change ↗ |
| Aug 7, 2025 | Results ↗ |
| Jun 13, 2025 | Shareholder vote ↗ |
| May 8, 2025 | Results ↗ |